Stifel raised the firm’s price target on Apogee Therapeutics (APGE) to $133 from $95 and keeps a Buy rating on the shares following positive Phase 1b asthma data for zumilokibart. Apogee’s Phase 1b data “represents clear evidence of activity” that should support accrual of meaningful credit in the stock and further support for the pipeline-in-a product thesis, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics Stock (APGE) Plunges despite ‘Positive’ Asthma Drug Trial
- Apogee Therapeutics Reports Positive Phase 1b Asthma Results
- Apogee Therapeutics reports ‘positive’ results from Phase 1b zumilokibart trial
- J&J failure likely a ‘clearing event’ for Apogee Therapeutics, says BTIG
- Apogee Therapeutics price target lowered to $81 from $82 at BofA